Literature DB >> 7539084

Anti-beta 1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops.

G Wallukat1, A Wollenberger, R Morwinski, H F Pitschner.   

Abstract

In a preceding communication (Wallukat et al., 1992, Z Kardiol 81 [Suppl. 4]: 79-83), it was reported that synthetic peptides, corresponding in amino acid sequence to either the first or the second extracellular loop of the human beta 1-adrenoceptor, selectively suppressed the metoprolol- and bisoprolol-sensitive positive chronotropic action exerted in cultures of beating neonatal rat cardiomyocytes by the serum immunoglobulin fraction of patients with myocarditis and idiopathic dilated cardiomyopathy (DCM) and by affinity-purified autoantibodies from that fraction. These observations added to existing evidence that these antibodies were directed against the beta 1-adrenoceptor and might thus contribute to the harmful chronic cardiac adrenergic drive to which patients with DCM are believed to be exposed. Specifically, they pointed to the putative first and second extracellular loops of this receptor (these loops are each identical in man and the rat) as the sites of epitopes recognized by the chronotropically active, beta 1-agonistic autoantibodies. Now we report on the mapping of these epitopes with the help of two series of short synthetic overlap peptides, one series forming part of the first and the other of the second extracellular loop of the beta 1-adrenoceptor. Inhibition of the positive chronotropic response of cultured rat cardiomyocytes to the anti-beta 1-receptor autoantibodies (EC50 = 0.14 +/- 0.01 nM) from the serum immunoglobulin fraction of patients with DCM was taken as reflecting the neutralization of these antibodies by a particular overlap peptide. In this way the sequences S-F-F-C-E-L (residues 129-134) and A-R-R-C-Y-N-D (residues 206-212) emerged as the dominant epitopes in the first and second extracellular loops, respectively, followed with respect to neutralizing ability by the first loop sequence E-Y-G-S-F-F (residues 126-131) and the second loop sequences H-W-W-R-A-E (residues 197-202) and P-K-C-C-D-F (residues 213-218). Synthetic peptides corresponding to the sequences of the third extracellular loop of the beta 1-receptor (residues 346-356) and of the second extracellular loop of the human beta 2-receptor (residues 172-197) failed to neutralize the beta 1-agonistic autoantibodies. Using dithiothreitol as a reducing agent a disulfide bridge between cysteine 132 in the first and cysteine 209 in the second extracellular loop was considered to be essential for the chronotropic action of these autoantibodies.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539084     DOI: 10.1016/s0022-2828(08)80036-3

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  38 in total

1.  Autoantibodies in the sera of patients with rheumatic heart disease: characterization of myocardial antigens by two-dimensional immunoblotting and N-terminal sequence analysis.

Authors:  D Tontsch; S Pankuweit; B Maisch
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

2.  Anti beta1-adrenoceptor autoantibodies analyzed in spontaneously beating neonatal rat heart myocyte cultures-comparison of methods.

Authors:  G Wallukat; E Nissen
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-03       Impact factor: 2.416

3.  Pathophysiological role of autoantibodies against G-protein-coupled receptors in the cardiovascular system.

Authors:  Wolfgang Schulze; Rudolf Kunze; Gerd Wallukat
Journal:  Exp Clin Cardiol       Date:  2005

Review 4.  Autoantibodies as Endogenous Modulators of GPCR Signaling.

Authors:  Meredith A Skiba; Andrew C Kruse
Journal:  Trends Pharmacol Sci       Date:  2020-12-24       Impact factor: 14.819

Review 5.  Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases.

Authors:  Gerd Wallukat; Ingolf Schimke
Journal:  Semin Immunopathol       Date:  2014-04-29       Impact factor: 9.623

Review 6.  Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

Review 7.  Cardiac troponins and autoimmunity: their role in the pathogenesis of myocarditis and of heart failure.

Authors:  Ziya Kaya; Hugo A Katus; Noel R Rose
Journal:  Clin Immunol       Date:  2009-05-14       Impact factor: 3.969

8.  Opposing cardiac effects of autoantibody activation of β-adrenergic and M2 muscarinic receptors in cardiac-related diseases.

Authors:  Stavros Stavrakis; David C Kem; Eugene Patterson; Pedro Lozano; Shijun Huang; Bela Szabo; Madeleine W Cunningham; Ralph Lazzara; Xichun Yu
Journal:  Int J Cardiol       Date:  2010-01-06       Impact factor: 4.164

9.  Adoptive passive transfer of rabbit beta1-adrenoceptor peptide immune cardiomyopathy into the Rag2-/- mouse: participation of the ER stress.

Authors:  Jiahao Liu; Weike Mao; Chikao Iwai; Shuji Fukuoka; Raju Vulapalli; Huanlei Huang; Tingchung Wang; Virendra K Sharma; Shey-Shing Sheu; Michael Fu; Chang-Seng Liang
Journal:  J Mol Cell Cardiol       Date:  2007-11-24       Impact factor: 5.000

Review 10.  Recent insights into the role of autoimmunity in idiopathic dilated cardiomyopathy.

Authors:  Jason M Lappé; Clara M Pelfrey; W H Wilson Tang
Journal:  J Card Fail       Date:  2008-05-27       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.